Across‐Envelope Comparisons of Dynamic Histomorphometric Indices at Months 6 or 24 for Teriparatide and Zoledronic Acid in the Paired Biopsy Set
| Month 6 | Month 24 | |||||||
| Indices | Cancellous | Endocortical | Intracortical | Periosteal | Cancellous | Endocortical | Intracortical | Periosteal |
| Teriparatide | ||||||||
| MS/BS (%) | 4.44 | 19.06 | 17.49† | 0.71* | 3.06 | 5.82 | 13.34‡ | 1.91 |
| (2.18, 10.75) | (7.67, 26.05) | (14.67, 30.36) | (0.00, 1.89) | (1.49, 4.58) | (3.10, 7.08) | (12.55, 15.87) | (0.87, 2.21) | |
| n = 7 | n = 7 | n = 7 | n = 7 | n = 9 | n = 9 | n = 9 | n = 9 | |
| BFR/BS (mm3/mm2/year) | 0.0110 | 0.0334 | 0.0502† | 0.0008* | 0.0057 | 0.0090 | 0.0310‡ | 0.0021 |
| (0.0040, 0.0231) | (0.0159, 0.0411) | (0.0417, 0.0750) | (0.0000, 0.0021) | (0.0022, 0.0061) | (0.0049, 0.0100) | (0.0276, 0.0416) | (0.0016, 0.0023) | |
| n = 7 | n = 7 | n = 7 | n = 7 | n = 9 | n = 9 | n = 9 | n = 9 | |
| Ac.f (per year) | 0.35 | 0.92 | — | — | 0.19 | 0.24 | — | — |
| (0.16, 0.74) | (0.46, 1.09) | (0.08, 0.20) | (0.14, 0.29) | |||||
| n = 7 | n = 7 | n = 9 | n = 9 | |||||
| MAR (μm/day) | 0.59 | 0.44 | 0.72* | 0.30 | 0.41 | 0.42 | 0.59‡ | 0.30* |
| (0.50, 0.63) | (0.42, 0.57) | (0.68, 0.78) | (0.30, 0.30) | (0.37, 0.51) | (0.37, 0.45) | (0.57, 0.69) | (0.30, 0.32) | |
| n = 7 | n = 7 | n = 7 | n = 5 | n = 9 | n = 9 | n = 9 | n = 8 | |
| Zoledronic acid | ||||||||
| MS/BS (%) | 0.00 | 0.32 | 0.58 | 0.00 | 0.04 | 0.00 | 2.09* | 0.00 |
| (0.00, 0.15) | (0.00, 0.80) | (0.00, 1.84) | (0.00, 0.00) | (0.00, 0.30) | (0.00, 0.91) | (0.31, 8.60) | (0.00, 0.06) | |
| n = 9 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | n = 8 | n = 8 | |
| BFR/BS (mm3/mm2/year) | 0.0000 | 0.0003 | 0.0007 | 0.0000 | 0.0000 | 0.0000 | 0.0039* | 0.0000 |
| (0.0000, 0.0002) | (0.0000, 0.0009) | (0.0000, 0.0037) | (0.0000, 0.0000) | (0.0000, 0.0004) | (0.0000, 0.0016) | (0.0003, 0.0186) | (0.0000, 0.0007) | |
| n = 9 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | n = 8 | n = 8 | |
| Ac.f (per year) | 0.00 | 0.01 | — | — | 0.00 | 0.00 | — | — |
| (0.00, 0.01) | (0.00, 0.03) | (0.00, 0.01) | (0.00, 0.04) | |||||
| n = 9 | n = 9 | n = 8 | n = 8 | |||||
| MAR (μm/day) | 0.37 | 0.30 | 0.55 | 0.32 | 0.30 | 0.44 | 0.52 | 0.30 |
| (0.30, 0.51) | (0.30, 0.40) | (0.40, 0.65) | (0.30, 0.34) | (0.30, 0.32) | (0.30, 0.52) | (0.30, 0.61) | (0.30, 0.30) | |
| n = 3 | n = 5 | n = 5 | n = 2 | n = 4 | n = 3 | n = 7 | n = 2 | |
| Month 6 | Month 24 | |||||||
| Indices | Cancellous | Endocortical | Intracortical | Periosteal | Cancellous | Endocortical | Intracortical | Periosteal |
| Teriparatide | ||||||||
| MS/BS (%) | 4.44 | 19.06 | 17.49† | 0.71* | 3.06 | 5.82 | 13.34‡ | 1.91 |
| (2.18, 10.75) | (7.67, 26.05) | (14.67, 30.36) | (0.00, 1.89) | (1.49, 4.58) | (3.10, 7.08) | (12.55, 15.87) | (0.87, 2.21) | |
| n = 7 | n = 7 | n = 7 | n = 7 | n = 9 | n = 9 | n = 9 | n = 9 | |
| BFR/BS (mm3/mm2/year) | 0.0110 | 0.0334 | 0.0502† | 0.0008* | 0.0057 | 0.0090 | 0.0310‡ | 0.0021 |
| (0.0040, 0.0231) | (0.0159, 0.0411) | (0.0417, 0.0750) | (0.0000, 0.0021) | (0.0022, 0.0061) | (0.0049, 0.0100) | (0.0276, 0.0416) | (0.0016, 0.0023) | |
| n = 7 | n = 7 | n = 7 | n = 7 | n = 9 | n = 9 | n = 9 | n = 9 | |
| Ac.f (per year) | 0.35 | 0.92 | — | — | 0.19 | 0.24 | — | — |
| (0.16, 0.74) | (0.46, 1.09) | (0.08, 0.20) | (0.14, 0.29) | |||||
| n = 7 | n = 7 | n = 9 | n = 9 | |||||
| MAR (μm/day) | 0.59 | 0.44 | 0.72* | 0.30 | 0.41 | 0.42 | 0.59‡ | 0.30* |
| (0.50, 0.63) | (0.42, 0.57) | (0.68, 0.78) | (0.30, 0.30) | (0.37, 0.51) | (0.37, 0.45) | (0.57, 0.69) | (0.30, 0.32) | |
| n = 7 | n = 7 | n = 7 | n = 5 | n = 9 | n = 9 | n = 9 | n = 8 | |
| Zoledronic acid | ||||||||
| MS/BS (%) | 0.00 | 0.32 | 0.58 | 0.00 | 0.04 | 0.00 | 2.09* | 0.00 |
| (0.00, 0.15) | (0.00, 0.80) | (0.00, 1.84) | (0.00, 0.00) | (0.00, 0.30) | (0.00, 0.91) | (0.31, 8.60) | (0.00, 0.06) | |
| n = 9 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | n = 8 | n = 8 | |
| BFR/BS (mm3/mm2/year) | 0.0000 | 0.0003 | 0.0007 | 0.0000 | 0.0000 | 0.0000 | 0.0039* | 0.0000 |
| (0.0000, 0.0002) | (0.0000, 0.0009) | (0.0000, 0.0037) | (0.0000, 0.0000) | (0.0000, 0.0004) | (0.0000, 0.0016) | (0.0003, 0.0186) | (0.0000, 0.0007) | |
| n = 9 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | n = 8 | n = 8 | |
| Ac.f (per year) | 0.00 | 0.01 | — | — | 0.00 | 0.00 | — | — |
| (0.00, 0.01) | (0.00, 0.03) | (0.00, 0.01) | (0.00, 0.04) | |||||
| n = 9 | n = 9 | n = 8 | n = 8 | |||||
| MAR (μm/day) | 0.37 | 0.30 | 0.55 | 0.32 | 0.30 | 0.44 | 0.52 | 0.30 |
| (0.30, 0.51) | (0.30, 0.40) | (0.40, 0.65) | (0.30, 0.34) | (0.30, 0.32) | (0.30, 0.52) | (0.30, 0.61) | (0.30, 0.30) | |
| n = 3 | n = 5 | n = 5 | n = 2 | n = 4 | n = 3 | n = 7 | n = 2 | |
Values are shown as median (interquartile range). Note: The median values for MS/BS and BFR/BS at 24 months either continued to exceed (intracortical envelope; p < 0.05) or were similar to (endocortical envelope; NS, p ≥ 0.7) the values observed in the cancellous envelope at month 6 (TPTD, n = 6 at both time points; ZOL, n = 8 at both time points). Values of p are from the Wilcoxon rank sum test. Symbols indicate significant differences between the other 3 envelopes and the cancellous envelope at month 6 or month 24: *p < 0.05,†p ≤ 0.01, ‡p ≤ 0.001.
TPTD = teriparatide; ZOL = zoledronic acid. Values are shown as median (interquartile range); values in the cancellous envelope are in bold type as they served as a reference to compare the activity in the other 3 bone envelopes at either 6 or 24 months.
Across‐Envelope Comparisons of Dynamic Histomorphometric Indices at Months 6 or 24 for Teriparatide and Zoledronic Acid in the Paired Biopsy Set
| Month 6 | Month 24 | |||||||
| Indices | Cancellous | Endocortical | Intracortical | Periosteal | Cancellous | Endocortical | Intracortical | Periosteal |
| Teriparatide | ||||||||
| MS/BS (%) | 4.44 | 19.06 | 17.49† | 0.71* | 3.06 | 5.82 | 13.34‡ | 1.91 |
| (2.18, 10.75) | (7.67, 26.05) | (14.67, 30.36) | (0.00, 1.89) | (1.49, 4.58) | (3.10, 7.08) | (12.55, 15.87) | (0.87, 2.21) | |
| n = 7 | n = 7 | n = 7 | n = 7 | n = 9 | n = 9 | n = 9 | n = 9 | |
| BFR/BS (mm3/mm2/year) | 0.0110 | 0.0334 | 0.0502† | 0.0008* | 0.0057 | 0.0090 | 0.0310‡ | 0.0021 |
| (0.0040, 0.0231) | (0.0159, 0.0411) | (0.0417, 0.0750) | (0.0000, 0.0021) | (0.0022, 0.0061) | (0.0049, 0.0100) | (0.0276, 0.0416) | (0.0016, 0.0023) | |
| n = 7 | n = 7 | n = 7 | n = 7 | n = 9 | n = 9 | n = 9 | n = 9 | |
| Ac.f (per year) | 0.35 | 0.92 | — | — | 0.19 | 0.24 | — | — |
| (0.16, 0.74) | (0.46, 1.09) | (0.08, 0.20) | (0.14, 0.29) | |||||
| n = 7 | n = 7 | n = 9 | n = 9 | |||||
| MAR (μm/day) | 0.59 | 0.44 | 0.72* | 0.30 | 0.41 | 0.42 | 0.59‡ | 0.30* |
| (0.50, 0.63) | (0.42, 0.57) | (0.68, 0.78) | (0.30, 0.30) | (0.37, 0.51) | (0.37, 0.45) | (0.57, 0.69) | (0.30, 0.32) | |
| n = 7 | n = 7 | n = 7 | n = 5 | n = 9 | n = 9 | n = 9 | n = 8 | |
| Zoledronic acid | ||||||||
| MS/BS (%) | 0.00 | 0.32 | 0.58 | 0.00 | 0.04 | 0.00 | 2.09* | 0.00 |
| (0.00, 0.15) | (0.00, 0.80) | (0.00, 1.84) | (0.00, 0.00) | (0.00, 0.30) | (0.00, 0.91) | (0.31, 8.60) | (0.00, 0.06) | |
| n = 9 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | n = 8 | n = 8 | |
| BFR/BS (mm3/mm2/year) | 0.0000 | 0.0003 | 0.0007 | 0.0000 | 0.0000 | 0.0000 | 0.0039* | 0.0000 |
| (0.0000, 0.0002) | (0.0000, 0.0009) | (0.0000, 0.0037) | (0.0000, 0.0000) | (0.0000, 0.0004) | (0.0000, 0.0016) | (0.0003, 0.0186) | (0.0000, 0.0007) | |
| n = 9 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | n = 8 | n = 8 | |
| Ac.f (per year) | 0.00 | 0.01 | — | — | 0.00 | 0.00 | — | — |
| (0.00, 0.01) | (0.00, 0.03) | (0.00, 0.01) | (0.00, 0.04) | |||||
| n = 9 | n = 9 | n = 8 | n = 8 | |||||
| MAR (μm/day) | 0.37 | 0.30 | 0.55 | 0.32 | 0.30 | 0.44 | 0.52 | 0.30 |
| (0.30, 0.51) | (0.30, 0.40) | (0.40, 0.65) | (0.30, 0.34) | (0.30, 0.32) | (0.30, 0.52) | (0.30, 0.61) | (0.30, 0.30) | |
| n = 3 | n = 5 | n = 5 | n = 2 | n = 4 | n = 3 | n = 7 | n = 2 | |
| Month 6 | Month 24 | |||||||
| Indices | Cancellous | Endocortical | Intracortical | Periosteal | Cancellous | Endocortical | Intracortical | Periosteal |
| Teriparatide | ||||||||
| MS/BS (%) | 4.44 | 19.06 | 17.49† | 0.71* | 3.06 | 5.82 | 13.34‡ | 1.91 |
| (2.18, 10.75) | (7.67, 26.05) | (14.67, 30.36) | (0.00, 1.89) | (1.49, 4.58) | (3.10, 7.08) | (12.55, 15.87) | (0.87, 2.21) | |
| n = 7 | n = 7 | n = 7 | n = 7 | n = 9 | n = 9 | n = 9 | n = 9 | |
| BFR/BS (mm3/mm2/year) | 0.0110 | 0.0334 | 0.0502† | 0.0008* | 0.0057 | 0.0090 | 0.0310‡ | 0.0021 |
| (0.0040, 0.0231) | (0.0159, 0.0411) | (0.0417, 0.0750) | (0.0000, 0.0021) | (0.0022, 0.0061) | (0.0049, 0.0100) | (0.0276, 0.0416) | (0.0016, 0.0023) | |
| n = 7 | n = 7 | n = 7 | n = 7 | n = 9 | n = 9 | n = 9 | n = 9 | |
| Ac.f (per year) | 0.35 | 0.92 | — | — | 0.19 | 0.24 | — | — |
| (0.16, 0.74) | (0.46, 1.09) | (0.08, 0.20) | (0.14, 0.29) | |||||
| n = 7 | n = 7 | n = 9 | n = 9 | |||||
| MAR (μm/day) | 0.59 | 0.44 | 0.72* | 0.30 | 0.41 | 0.42 | 0.59‡ | 0.30* |
| (0.50, 0.63) | (0.42, 0.57) | (0.68, 0.78) | (0.30, 0.30) | (0.37, 0.51) | (0.37, 0.45) | (0.57, 0.69) | (0.30, 0.32) | |
| n = 7 | n = 7 | n = 7 | n = 5 | n = 9 | n = 9 | n = 9 | n = 8 | |
| Zoledronic acid | ||||||||
| MS/BS (%) | 0.00 | 0.32 | 0.58 | 0.00 | 0.04 | 0.00 | 2.09* | 0.00 |
| (0.00, 0.15) | (0.00, 0.80) | (0.00, 1.84) | (0.00, 0.00) | (0.00, 0.30) | (0.00, 0.91) | (0.31, 8.60) | (0.00, 0.06) | |
| n = 9 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | n = 8 | n = 8 | |
| BFR/BS (mm3/mm2/year) | 0.0000 | 0.0003 | 0.0007 | 0.0000 | 0.0000 | 0.0000 | 0.0039* | 0.0000 |
| (0.0000, 0.0002) | (0.0000, 0.0009) | (0.0000, 0.0037) | (0.0000, 0.0000) | (0.0000, 0.0004) | (0.0000, 0.0016) | (0.0003, 0.0186) | (0.0000, 0.0007) | |
| n = 9 | n = 9 | n = 9 | n = 9 | n = 8 | n = 8 | n = 8 | n = 8 | |
| Ac.f (per year) | 0.00 | 0.01 | — | — | 0.00 | 0.00 | — | — |
| (0.00, 0.01) | (0.00, 0.03) | (0.00, 0.01) | (0.00, 0.04) | |||||
| n = 9 | n = 9 | n = 8 | n = 8 | |||||
| MAR (μm/day) | 0.37 | 0.30 | 0.55 | 0.32 | 0.30 | 0.44 | 0.52 | 0.30 |
| (0.30, 0.51) | (0.30, 0.40) | (0.40, 0.65) | (0.30, 0.34) | (0.30, 0.32) | (0.30, 0.52) | (0.30, 0.61) | (0.30, 0.30) | |
| n = 3 | n = 5 | n = 5 | n = 2 | n = 4 | n = 3 | n = 7 | n = 2 | |
Values are shown as median (interquartile range). Note: The median values for MS/BS and BFR/BS at 24 months either continued to exceed (intracortical envelope; p < 0.05) or were similar to (endocortical envelope; NS, p ≥ 0.7) the values observed in the cancellous envelope at month 6 (TPTD, n = 6 at both time points; ZOL, n = 8 at both time points). Values of p are from the Wilcoxon rank sum test. Symbols indicate significant differences between the other 3 envelopes and the cancellous envelope at month 6 or month 24: *p < 0.05,†p ≤ 0.01, ‡p ≤ 0.001.
TPTD = teriparatide; ZOL = zoledronic acid. Values are shown as median (interquartile range); values in the cancellous envelope are in bold type as they served as a reference to compare the activity in the other 3 bone envelopes at either 6 or 24 months.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
